This study focuses on patients with Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic change called RAS G12D mutation. The study will test a new medication called zoldonrasib (also known as RMC-9805) in patients who have already received previous cancer treatments. This type of lung cancer occurs when cells in the lungs grow abnormally and form tumors.

The purpose of this research is to determine how well zoldonrasib works in treating patients with this specific type of lung cancer. The medication comes in tablet form and is taken by mouth. During the study, patients will receive zoldonrasib daily, with the maximum daily dose being 1200 mg. The treatment period may last up to 9 months.

Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will check the size of tumors and watch for any changes in the patient’s condition. The study will also look at how long the treatment remains effective and track any side effects that may occur. Regular medical examinations and blood tests will be performed to ensure patient safety during the treatment period.